GlassScriptPhysician profile
Mark S Gosnell
NPI 1003949348
$3,694.80
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $766 · 2021: $1,183 · 2022: $102.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $856.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $502.02 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.17 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $228.09 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $183.52 | 2019-2021 | |
| Mylan Specialty L.P. | $180.67 | 2019-2021 | |
| Grifols USA, LLC | $173.71 | 2019-2021 | |
| Philips North America LLC | $167.88 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $121.36 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.44 | 2020-2021 | |
| Shire North American Group INC | $83.52 | 2019 | |
| Harmony Biosciences LLC | $82.92 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $77.11 | 2021 | |
| Genzyme Corporation | $62.41 | 2019-2020 | |
| Advanced Respiratory, INC | $61.27 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $53.84 | 2019 | |
| Circassia INC. | $50.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.05 | 2019-2020 | |
| Insmed, INC. | $32.38 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $27.05 | 2019 | |
| Genentech USA, INC. | $21.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.47 | 2019 | |
| Gilead Sciences, INC. | $14.10 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$9,209.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gosnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.